Information on 22q11DS

Basic details

Name: DiGeorge syndrome | Acronym: 22q11DS
Alt. names: 22q11.2 deletion syndrome

Gene: TBX1 | MOI: Autosomal dominant | Mechanism of action:

No. of cases in DB: 2 | First reported in: 2003

Last updated on: 2023-02-28 16:41:18 by Andrés Caballero-Oteyza

OMIM: 188400

Orphanet: 567

MONDO: -

DOID: -

ClinGen:

Description

22q11.2 deletion syndrome shows a variable clinical phenotype that can range from mild to severe. Congenital heart defects (two-thirds of cases) include mainly conotruncal malformations such as ventricular septal defect, truncus arteriosus, tetralogy of Fallot and interrupted aortic arch. Anomalies of the aortic arch and vascular ring are frequent. More than 65% of patients present with palatal anomalies (e.g. velopharyngeal incompetence, submucous cleft palate or bifid uvula) that may lead to hypernasal speech and feeding difficulties. Overt cleft palate and cleft lip are less frequent. Most patients display subtle but recognizable facial features (e.g. ptosis, hypertelorism, epicanthal folds, prominent nasal root, malar flatness, small ears). Immune deficiency is the consequence of thymic aplasia/hypoplasia and improvement in T-cell production occurs over time. Patients have a higher risk of developing an autoimmune disease such as idiopathic thrombocytopenic purpura and juvenile idiopathic arthritis. Hypocalcemia as a consequence of hypoparathyroidism is frequent in the neonatal period and usually resolves but can reappear at any age. Additional clinical findings may include gastrointestinal anomalies (intestinal malrotation, imperforate anus), hearing loss, renal anomalies (renal agenesis), dental anomalies (enamel hypoplasia), and skeletal anomalies (scoliosis, clubfoot). Learning difficulties and developmental delay are almost always present. Psychiatric illness (anxiety, depression, schizophrenia) and Parkinson's disease are more frequent than in the general population.[ORPHANET]

Management

Management is symptom-based and requires a multidisciplinary approach. It may consist of heart and/or palate surgery, nasogastric feeding, calcium supplementation, occupational, physical, and speech therapy, educational and behavioral therapy, as well as support and treatment for psychiatric disease. Tonsillectomy is not recommended unless indicated by a center of expertise. A regular surveillance of calcium, thyroid function and blood cell count is necessary. Immune function must be evaluated before administering live vaccines.[orphanet]

Please mind that full curation of this condition has not been completed yet. It is currently ongoing.

2 reported cases added to GenIA

SubjectID Sex Fam.ID AD AFM Validity Country Population Reference & Pub.code
101091arrow icon M 210911 15 PMID:34975878 [Fam.F057:P057]; PMID:35486341 [P180]
102224arrow icon F 214919 59 Germany German PMID:35486341 [P017]

AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).

Summary of clinical findings

[Considering only Definitive and Possible cases]

Rank Clinical term Present Absent Unreported
1 Drug allergyarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
2 (unusual) Respiratory tract infectionarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
3 Autoimmunityarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
4 Abnormal lymphoproliferationarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
5 Autoimmune hemolytic anemiaarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
6 Autoimmune cytopeniaarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
7 Lung diseasearrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
8 Atopyarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
9 Allergyarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
10 Hypogammaglobulinemiaarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
11 Pneumoniaarrow icon 2 (99.9%) 0 (0.0%) 0 (0.0%)
12 Decreased proportion of switched memory B cellsarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
13 Increased proportion of CD21low B cellsarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
14 Reduced ab-response to tetanus vaccinearrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
15 negative ab-response to diphtheria vaccinearrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
16 Seizuresarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
17 Recurrent upper respiratory tract infectionarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
18 Lymphadenopathyarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
19 Absent ab-response to pneumococcal polysaccharide vaccinearrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
20 Decreased proportion of plasmablastsarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
21 Recurrent feversarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
22 Splenomegalyarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
23 Autoimmune thrombocytopeniaarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
24 Granulomatous-lymphocytic interstitial lung diseasearrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
25 Reduced proportion of naive CD4 T cellsarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
26 Drug-induced osteoporosisarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
27 (unusual) Epstein-Barr virus infectionarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
28 Intestinal lymphoid nodular hyperplasiaarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
29 Hepatic granulomatosisarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
30 Leukopeniaarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
31 Varicella zoster virus infectionarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
32 Aortic regurgitationarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
33 Sciaticaarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
34 (unusual) Viral infectionarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
35 Diffuse alveolar hemorrhagearrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
36 Henoch-Schönlein Purpuraarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
37 Steatocystoma multiplexarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
38 Arthritisarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
39 cholelithiasisarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
40 Iron deficiency anemiaarrow icon 1 (50.0%) 0 (0.0%) 1 (50.0%)
41 Antinuclear antibodiesarrow icon 0 (0.0%) 2 (99.9%) 0 (0.0%)
42 Rheumatoid factor positivearrow icon 0 (0.0%) 1 (50.0%) 1 (50.0%)
43 Autoimmune antibody positivityarrow icon 0 (0.0%) 2 (99.9%) 0 (0.0%)

Please mind that full curation of this condition has not been completed yet. It is currently ongoing.

Summary of treatment outcomes

[Considering only Definitive and Possible cases]

Treatment ⓘ Responses & clinical indications

Please mind that full curation of this condition has not been completed yet. It is currently ongoing.